News Search Results
Jun 20, 2025, 10:03 ET European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome)
hemorrhage, hypertension, tachycardia, bilirubinemia, hyperglycemia, increased creatinine, hypomagnesemia, edema, pharyngitis, epistaxis, dyspnea, insomnia, anxiety, high glucose, low albuminIn patients with AML–fever, weight loss, nausea, vomiting, anorexia, skin reactions, metabolic laboratory
More news about: Partner Therapeutics, Inc.
Jun 19, 2025, 08:27 ET Happy Ring Earns Second FDA Clearance--Now Approved for At-Home Sleep Testing to Simplify the Diagnosis and Treatment of Sleep Apnea and Related Health Conditions
U.S. Food and Drug Administration has cleared the Happy Ring as a class II medical device to facilitate the diagnosis of obstructive sleep apnea, insomnia, and other sleep related conditions in the home. This new clearance builds on the
More news about: Happy Health, Inc.
Jun 18, 2025, 12:03 ET Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category
tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum,
More news about: Lindus Health
Jun 18, 2025, 06:48 ET Mallinckrodt Announces Publication of Real-World Insights on Patient Experience with Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
disorders. Monitor for signs of perforation and bleedingActhar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravatedPatients with comorbid
More news about: Mallinckrodt plc
Jun 16, 2025, 15:40 ET UPSHER-SMITH SHOWCASES ITS COMMITMENT TO DUCHENNE MUSCULAR DYSTROPHY COMMUNITY AS A TRUSTED PARTNER IN PEDIATRIC RARE DISEASES AT THE PARENT PROJECT MUSCULAR DYSTROPHY (PPMD) 2025 ANNUAL CONFERENCE
inflammatory bowel disease. Signs and symptoms may be masked.Behavioral and Mood Disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis. Symptoms typically emerge within a few days or weeks of starting treatment and
More news about: Upsher-Smith Laboratories, LLC
Jun 12, 2025, 08:00 ET Groundbreaking Global Study Underscores Overlooked Health Changes During Menopause
Women may experience up to a 33% increase in nighttime awakenings, averaging between 3 and 4 wake-ups per nightSleep disorders, including insomnia and sleep apnea, increase by 374%Body compositionAbdominal and visceral fat naturally increase by 43%Cardiovascular
More news about: Withings
Jun 11, 2025, 10:28 ET Cannabidiol Market Size worth $22.05 billion, Globally, by 2030 - Exclusive Report by The Research Insights
non-psychoactive cannabis component that has become popular because it successfully manages multiple health issues such as chronic pain, anxiety, insomnia, inflammation and epilepsy. The endorsement of Epidiolex by the U.S. FDA marked a major turning point for CBD validation as a treatment when the medication
More news about: The Research Insights
Jun 10, 2025, 17:59 ET Insomnia Cookies launches next phase of growth alongside Verlinvest and Mistral Equity Partners
Founder of Insomnia Cookies. "We're united by a shared vision: to establish Insomnia as the undisputed leader in the indulgence category. With this support, we're poised to rapidly scale and deliver more warm, delicious cookies to Insomniacs around the world." "We believe Insomnia Cookies has
More news about: Insomnia Cookies
Jun 09, 2025, 18:00 ET Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
patients at recommended doses, one patient reported insomnia following abrupt discontinuation of XYWAV. In the XYWAV clinical trial in adult idiopathic hypersomnia patients at recommended doses, six patients reported insomnia, two patients reported early insomnia, and one patient reported visual and auditory
More news about: Jazz Pharmaceuticals plc
Jun 09, 2025, 11:35 ET Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®
New collaboration delivers 50% off prescription sleep support for new customers who are struggling with insomnia and sleep disruption DALLAS, June
More news about: Health-E Commerce
Jun 03, 2025, 10:45 ET DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
infection. The most common adverse reactions with combination therapy (≥20 percent for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation,
More news about: Johnson & Johnson
Jun 03, 2025, 08:00 ET Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
increased ALT, edema, dyspnea, decreased appetite, vomiting, dizziness, COVID-19, headache, abdominal pain, hemorrhage, urinary tract infection, cough, insomnia, increased bilirubin, weight decreased, arrhythmia, fall, and pyrexia. Serious adverse reactions reported in >2% of patients included COVID-19
More news about: Johnson & Johnson
Jun 02, 2025, 08:04 ET IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
IMDELLTRA®, including 10% Grade 3. The most frequent neurologic toxicities were headache (14%), peripheral neuropathy (7%), dizziness (7%), insomnia (6%), muscular weakness (3.7%), delirium (2.1%), syncope (1.6%), and neurotoxicity (1.1%).ICANS occurred in 9% of IMDELLTRA®-treated
More news about: Amgen
May 29, 2025, 07:30 ET Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
patients at recommended doses, one patient reported insomnia following abrupt discontinuation of XYWAV. In the XYWAV clinical trial in adult idiopathic hypersomnia patients at recommended doses, six patients reported insomnia, two patients reported early insomnia, and one patient reported visual and auditory
More news about: Jazz Pharmaceuticals plc
May 20, 2025, 18:21 ET U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
infection. The most common adverse reactions with combination therapy (≥20 percent for any combination) include fatigue, nausea, diarrhea, dyspnea, insomnia, headache, pyrexia, cough, muscle spasms, back pain, vomiting, hypertension, upper respiratory tract infection, peripheral sensory neuropathy, constipation,
More news about: Johnson & Johnson
May 19, 2025, 08:17 ET SK Life Science Launches Its Second National Ad, Continuing to Lead with the Only Direct-to-Consumer Commercial for an Anti-Seizure Drug in the U.S.
dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes
More news about: SK Life Science, Inc.
May 14, 2025, 06:52 ET Mallinckrodt Presents Data on Real-World Outcomes with Acthar® Gel (repository corticotropin injection) at the International Congress on Systemic Lupus Erythematosus (LUPUS 2025)
disorders. Monitor for signs of perforation and bleedingActhar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression to psychosis. Existing conditions may be aggravatedPatients with comorbid
More news about: Mallinckrodt plc
May 07, 2025, 16:01 ET Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results
expected in 2026.HETLIOZ® (tasimelteon) HETLIOZ® clinical programs in pediatric insomnia and delayed sleep phase disorder (DSPD) are ongoing.Vanda's MAA for HETLIOZ® and HETLIOZ LQ® for SMS is pending with
More news about: Vanda Pharmaceuticals Inc.
May 01, 2025, 10:07 ET Nocturne launches on Kickstarter: a sound machine with high-precision noise masking capabilities
lookEven though Nocturne was designed to help with tinnitus, the company has heard from early backers who want to use the product to manage insomnia, focus at work, mask confidential conversations, and add to their bedroom or office aesthetic, among other things. Nocturne is
More news about: Measure Things LLC
Apr 29, 2025, 06:00 ET Industry and Scientific Leaders Announce Partnership to Combat the Opioid Epidemic
collect physiological signals and behavior traits that can (1) predict relapse and (2) be measured by wearable technologies, including heart rate, insomnia, physical inactivity, and physiological stress. Smartphones will also be used to capture mental health characteristics such as social isolation, patient-reported
More news about: Digital Medicine Society (DiMe)
Apr 23, 2025, 15:52 ET FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
recommendations: CDER took six months to submit a proposed order on the Hetlioz jet lag hearing request and likewise requested six months for the Hetlioz insomnia application. It is unfair for CDER and its lawyers to blame the recent reductions in force for their habitual institutional delays on hearing
More news about: Vanda Pharmaceuticals Inc.
Apr 22, 2025, 09:00 ET A Place to Heal: Virtue Recovery Center Stands with Veterans and Families Across the United States
accidents — suicide. That's heartbreaking. Take John Anderton — a former Marine who battled PTSD and severe insomnia. After being hospitalized for suicidal thoughts, he was denied a referral to a private rehab center. Shortly after, he took his own life. And sadly,
More news about: Virtue Recovery
Apr 22, 2025, 08:53 ET Parents of Army Soldier File Federal Lawsuits Alleging Army Cover-Up and Delayed Action Following Son's Suicide
following the Army medical personnel's failure to intervene after Noah displayed clear warning signs of suicidal ideation—including alcohol misuse, insomnia, and social withdrawal. Noah died by suicide on or around November 6, 2021; his body went undiscovered in his barracks.
More news about: Federal Practice Group
Apr 16, 2025, 11:10 ET Sleep Specialist and Otolaryngologist, Julie Zweig, M.D., is Featured as a 2025 Top Patient Rated Doctor by Find Local Doctors
insomnia, snoring, sleep apnea, nasal congestion, allergies, and hearing loss. Dr. Zweig specializes in hearing and hearing aids, offering comprehensive treatment
More news about: Julie Zweig, MD Integrative Sleep & ENT
Apr 14, 2025, 08:31 ET The Brain Cleaning of Sleep Now Achieved During Wakefulness
indeed induce brain cleansing. The bioengineered radiofrequency technology utilized has the potential to counter deleterious effects of insomnia and sleep deprivation on brain toxin cleansing and to even reduce the amount of sleep normally required for brain toxin cleansing. "An ability
More news about: RF Longevity